Keywords
Oropharyngeal cancer
Cancer
Oncology
Abstract
Human papillomavirus (HPV) is a known aetiological factor in the development of oropharyngeal squamous cell carcinomas (OPSCC), however it is a distinct disease to HPV-negative OPSCC. It is more prevalent in younger patients with fewer comorbidities and HPV status is most commonly detected by p16 immunohistochemistry, which acts as a surrogate marker. Until recently, the TNM staging model was wrongly predicting a poor prognosis for many patients by determining an imperfect overall stage, however this has been resolved by an updated edition. Current management of OPSCC is not determined by HPV-status but there are ongoing trials into treatment deintensification to reduce side effects but maintain OS. Furthermore, prognosis is drastically improved in HPV-positive OPSCC.
References
Faraji F, Eisele DW, Fakhry C. Emerging insights into recurrent and metastatic human papillomavirus-related oropharyngeal squamous cell carcinoma. Laryngoscope Investigative Otolaryngology 2017;2(1):10-18. Available from: https://doi.org/10.1002/lio2.37
Mehanna H, Evans M, Beasley M, et al. Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines. The Journal of Laryngology and Otology 2016;130(Suppl 2):S90-S96. Available from: https://doi.org/10.1017/S0022215116000505
Schache AG, Powell NG, Cuschieri KS et al. HPV-related oropharyngeal cancer in the United Kingdom: an evolution in understanding of disease etiology. Cancer Research 2016;76(22):6598-6606. Available from: https://doi.org/10.1158/0008-5472.CAN-16-0633
Howard JD, Chung CH. Biology of human papillomavirus–related oropharyngeal cancer. Seminars in Radiation Oncology 2012;22(3):187-93. Available from: https://doi.org/10.1016/j.semradonc.2012.03.002
Owadally W, Hurt C, Timmins H. et al. PATHOS: a phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for human papillomavirus (HPV) positive oropharyngeal cancer. BMC Cancer 2015;15(1):602. Available from: https://doi.org/10.1186/s12885-015-1598-x
Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated oropharyngeal cancer. Oral oncology 2014;50(5):380-86. Available from: https://doi.org/10.1016/j.oraloncology.2013.12.019
Hocking JS, Stein A, Conway EL, et al. Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. British Journal Of Cancer 2011;104:886. Available from: https://doi.org/10.1038/sj.bjc.6606091
Candotto V, Lauritano D, Nardone M, et al. HPV infection in the oral cavity: epidemiology, clinical manifestations and relationship with oral cancer. Oral & Implantology 2017;10(3):209-20. Available from: https://doi.org/10.11138/orl/2017.10.3.209
Walvik L, Svensson AB, Friborg J, et al. The association between human papillomavirus and oropharyngeal squamous cell Carcinoma: Reviewed according to the Bradford Hill criteria for causality. Oral Oncology 2016;63:61-65. Available from: https://doi.org/10.1016/j.oraloncology.2016.11.003
Spriggs CC, Laimins LA. Human papillomavirus and the DNA damage response: exploiting host repair pathways for viral replication. Viruses 2017;9(8):232. Available from: https://doi.org/10.3390/v9080232
Grønhøj Larsen C, Gyldenløve M, Jensen DH, et al. Correlation between human papillomavirus and p16 overexpression in oropharyngeal tumours: a systematic review. British Journal Of Cancer 2014;110:1587. Available from: https://doi.org/10.1038/bjc.2014.42
Marur S, D’Souza G, Westra WH, et al. HPV-associated head and neck cancer: a virus-related cancer epidemic. The Lancet Oncology 2010;11(8):781-89. Available from: https://doi.org/10.1016/S1470-2045(10)70017-6
Husain N, Neyaz A. Human papillomavirus associated head and neck squamous cell carcinoma: controversies and new concepts. Journal of Oral Biology and Craniofacial Research 2017;7(3):198-205. Available from: https://doi.org/10.1016/j.jobcr.2017.08.003
Okami K. Clinical features and treatment strategy for HPV-related oropharyngeal cancer. International Journal of Clinical Oncology 2016;21(5):827-35. Available from: https://doi.org/10.1007/s10147-016-1009-6
Götz C, Drecoll E, Straub M, et al. Impact of HPV infection on oral squamous cell carcinoma. Oncotarget 2016;7(47):76704-12. Available from: https://doi.org/10.18632/oncotarget.12501
Selcuk OT. Human papillomavirus positive oropharyngeal cancer: the general information. Egyptian Journal of Ear, Nose, Throat and Allied Sciences 2016;17(3):127-32. Available from: https://doi.org/10.1016/j.ejenta.2016.07.007
Fischer CA, Kampmann M, Zlobec I, et al. p16 expression in oropharyngeal cancer: its impact on staging and prognosis compared with the conventional clinical staging parameters. Annals of Oncology 2010;21(10):1961-6. Available from: https://doi.org/10.1093/annonc/mdq210
O’Rorke MA, Ellison MV, Murray LJ, et al. Human papillomavirus related head and neck cancer survival: A systematic review and meta-analysis. Oral Oncology 2012;48(12):1191-201. Available from: https://doi.org/10.1016/j.oraloncology.2012.06.019
Mazul AL, Taylor JM, Divaris K et al. Oral health and HPV-associated head and neck squamous cell carcinoma. Cancer 2017;123(1):71-80. Available from: https://doi.org/10.1002/cncr.30312
Dahlstrom KR, Calzada G, Hanby JD, et al. An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: A staging system in need of repair. Cancer 2013;119(1):81-89. Available from: https://doi.org/10.1002/cncr.27727
Scaffidi RM, Gerhardt J, Eisele C. Human papillomavirus-related oropharyngeal cancer in women. Journal of Midwifery & Women’s Health 2016;61(3):380-83. Available from: https://doi.org/10.1111/jmwh.12446
Dahlstrom KR, Anderson KS, Sturgis EM. Human papillomavirus-associated oropharyngeal cancer: not just white men anymore. JAMA Oncology 2016;3(2):161-162. Available from: https://doi.org/10.1001/jamaoncol.2016.3510
Buglione M, Maddalo M, Corvo R et al. Subgroup analysis according to human papillomavirus status and tumor site of a randomized phase ii trial comparing cetuximab and cisplatin combined with radiation therapy for locally advanced head and neck cancer. International Journal of Radiation Oncology, Biology, Physics 2017;97(3):462-72. Available from: https://doi.org/10.1016/j.ijrobp.2016.10.011
Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. New England Journal of Medicine 2010;363(1):24-35. Available from: https://doi.org/10.1056/NEJMoa0912217
Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012;307(7):693-703. Available from: https://doi.org/10.1001/jama.2012.101
Laskar S, Swain M. HPV positive oropharyngeal cancer and treatment deintensification: How pertinent is it? Journal of Cancer Research and Therapeutics 2015;11(1):6-9. Available from: https://doi.org/10.4103/0973-1482.151445
Dahlstrom KR, Garden AS, Willliam WN Jr et al. Proposed staging system for patients with HPV-related oropharyngeal cancer based on nasopharyngeal cancer N categories. Journal of Clinical Oncology 2016;34(16):1848-54. Available from: https://doi.org/10.1200/JCO.2015.64.6448
Rios Velazquez E, Hoebers F, Aerts HJ et al. Externally validated HPV-based prognostic nomogram for oropharyngeal carcinoma patients yields more accurate predictions than TNM staging. Radiother Oncol. 2014:113(3):324-330. Available from: https://doi.org/10.1016/j.radonc.2014.09.005